Cargando…

Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats

Hyperuricemia is the main cause of gout and involved in the occurrence of multiple diseases, such as hypertension, metabolic disorders and chronic kidney disease. Emerging evidence suggests that lactic acid bacteria (LAB) have shown the beneficial effects on the prevention or treatment of hyperurice...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanjun, Zhu, Jun, Lin, Guodong, Gao, Kan, Yu, Yunxia, Chen, Su, Chen, Lie, Chen, Zuoguo, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562091/
https://www.ncbi.nlm.nih.gov/pubmed/36245501
http://dx.doi.org/10.3389/fnut.2022.993951
_version_ 1784808095097028608
author Li, Yanjun
Zhu, Jun
Lin, Guodong
Gao, Kan
Yu, Yunxia
Chen, Su
Chen, Lie
Chen, Zuoguo
Li, Li
author_facet Li, Yanjun
Zhu, Jun
Lin, Guodong
Gao, Kan
Yu, Yunxia
Chen, Su
Chen, Lie
Chen, Zuoguo
Li, Li
author_sort Li, Yanjun
collection PubMed
description Hyperuricemia is the main cause of gout and involved in the occurrence of multiple diseases, such as hypertension, metabolic disorders and chronic kidney disease. Emerging evidence suggests that lactic acid bacteria (LAB) have shown the beneficial effects on the prevention or treatment of hyperuricemia. In this study, the urate-lowering effect of two LAB strains, Lacticaseibacillus rhamnosus 1155 (LR1155) and Limosilactobacillus fermentum 2644 (LF2644) on hyperuricemic rats were investigated. A hyperuricemic rat model was induced by the intragastric treatment of potassium oxonate, combined with a high purine diet. The oral administration of LR1155, LF2644, or a combination of LR1155 and LF2644 for 4 weeks significantly prevented the rise of the serum uric acid (UA) induced by hyperuricemia. LR1155 and LF2644 significantly elevated the fecal UA levels, increased the UA content and up-regulated gene expression of UA transporter, ATP-binding cassette subfamily G-2 (ABCG2), in colon and jejunum tissues, suggesting the accelerated UA excretion from the intestine. Besides, LR1155 significantly inhibited the activity of xanthine oxidase (XOD) in liver and serum, benefited the reduce of UA production. In addition, LF2644 strengthened the gut barrier functions through an up-regulation of the gene expressions for occluding and mucin2, accompanied with the reduced inflammatory indicators of lipopolysaccharide (LPS) and interleukin-1β (IL-1β) in hyperuricemic rat. Moreover, using 16s rDNA high-throughput sequencing of feces, LR1155 was shown to improve the hyperuricemia induced gut microbial dysbiosis. The genera Roseburia, Butyricicoccus, Prevotella, Oscillibacter, and Bifidobacterium may associate with the effect of LR1155 on microbiota in hyperuricemic rats. Collectively, the results indicated that LR1155 and LF2644 exhibit urate-lowering effects and could be used alone or in combination as a new adjuvant treatment for hyperuricemia.
format Online
Article
Text
id pubmed-9562091
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95620912022-10-15 Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats Li, Yanjun Zhu, Jun Lin, Guodong Gao, Kan Yu, Yunxia Chen, Su Chen, Lie Chen, Zuoguo Li, Li Front Nutr Nutrition Hyperuricemia is the main cause of gout and involved in the occurrence of multiple diseases, such as hypertension, metabolic disorders and chronic kidney disease. Emerging evidence suggests that lactic acid bacteria (LAB) have shown the beneficial effects on the prevention or treatment of hyperuricemia. In this study, the urate-lowering effect of two LAB strains, Lacticaseibacillus rhamnosus 1155 (LR1155) and Limosilactobacillus fermentum 2644 (LF2644) on hyperuricemic rats were investigated. A hyperuricemic rat model was induced by the intragastric treatment of potassium oxonate, combined with a high purine diet. The oral administration of LR1155, LF2644, or a combination of LR1155 and LF2644 for 4 weeks significantly prevented the rise of the serum uric acid (UA) induced by hyperuricemia. LR1155 and LF2644 significantly elevated the fecal UA levels, increased the UA content and up-regulated gene expression of UA transporter, ATP-binding cassette subfamily G-2 (ABCG2), in colon and jejunum tissues, suggesting the accelerated UA excretion from the intestine. Besides, LR1155 significantly inhibited the activity of xanthine oxidase (XOD) in liver and serum, benefited the reduce of UA production. In addition, LF2644 strengthened the gut barrier functions through an up-regulation of the gene expressions for occluding and mucin2, accompanied with the reduced inflammatory indicators of lipopolysaccharide (LPS) and interleukin-1β (IL-1β) in hyperuricemic rat. Moreover, using 16s rDNA high-throughput sequencing of feces, LR1155 was shown to improve the hyperuricemia induced gut microbial dysbiosis. The genera Roseburia, Butyricicoccus, Prevotella, Oscillibacter, and Bifidobacterium may associate with the effect of LR1155 on microbiota in hyperuricemic rats. Collectively, the results indicated that LR1155 and LF2644 exhibit urate-lowering effects and could be used alone or in combination as a new adjuvant treatment for hyperuricemia. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9562091/ /pubmed/36245501 http://dx.doi.org/10.3389/fnut.2022.993951 Text en Copyright © 2022 Li, Zhu, Lin, Gao, Yu, Chen, Chen, Chen and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Li, Yanjun
Zhu, Jun
Lin, Guodong
Gao, Kan
Yu, Yunxia
Chen, Su
Chen, Lie
Chen, Zuoguo
Li, Li
Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title_full Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title_fullStr Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title_full_unstemmed Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title_short Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
title_sort probiotic effects of lacticaseibacillus rhamnosus 1155 and limosilactobacillus fermentum 2644 on hyperuricemic rats
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562091/
https://www.ncbi.nlm.nih.gov/pubmed/36245501
http://dx.doi.org/10.3389/fnut.2022.993951
work_keys_str_mv AT liyanjun probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT zhujun probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT linguodong probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT gaokan probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT yuyunxia probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT chensu probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT chenlie probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT chenzuoguo probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats
AT lili probioticeffectsoflacticaseibacillusrhamnosus1155andlimosilactobacillusfermentum2644onhyperuricemicrats